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Patient-centredness is an accepted term and is perceived by healthcare professionals to be morally and ethically
desirable. We are motivated by the belief that this approach will improve the patient-professional experience of the
decision-making process and improve health outcomes. We acknowledge that patients, either as participants or as
co-investigators, have positive contributions to make to research. As the idiopathic pulmonary fibrosis (IPF) community
enters a new era of clinical research activity we consider that there is greater capacity for patient involvement and
partnership.
Patient involvement in research can be optimised through collaborations in the research design, study conduct, and
dissemination. There is increasing interest in using patient- reported outcomes (PROs), such as health-related quality
of life, and symptoms measures to inform decision-making and ensure patient perspectives are taken into account.
PROs are an essential component of specialist IPF services, to monitor and improve care delivery and to measure and
benchmark performance. In clinical trials, PROs can additionally be used to define entry criteria, evaluate efficacy of an
intervention, and evaluate adverse events. We suggest that there is a much wider scope for including patient-centred
PROs in clinical research and for creative thought in developing patient co-investigator roles.
Participation in research activity requires highly refined decision-making processes, particularly in a condition
such as IPF, which has an often unpredictable trajectory. The IPF research landscape has changed and the design and
conduct of clinical trials in IPF requires some radical rethinking. It is accepted that involving patients in the role of
co-investigators will impact the research questions we ask and result in study designs that are patient-centred.
IPF clinical trials have been hindered by the lack of availability of validated, disease-specific questionnaires. A
conservative approach appears to have been taken to the inclusion of generic symptom or quality of life measures as
PRO endpoints. Thus, the impact of new drugs on the quality of life of research participants demonstrates only minimal
benefit. It is time to refocus on a patient-centred approach with regards to the co-investigator role, PRO development,
and research participants.
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Patient-centredness, as a broad construct, has been dis-
cussed in the literature for more than three decades. It
experienced resurgence in the “Patients Included” initia-
tive [1], interfacing with patient and public involvement
in research. From the policy perspective, the Institute
of Medicine defines patient-centred care as a priority
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Patients diagnosed with idiopathic pulmonary fibrosis
(IPF) and their families have expressed a need for more
healthcare support and education [3, 4], including prompt
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and standardised approaches in cancer and chronic dis-
eases, IPF can have inherent diagnostic and management
challenges. A chronic, progressive, fibrotic lung disease, IPF
follows an unpredictable course; typically affecting older
people (who may have pre-existing co-morbidities) and has
a 5-year survival of only 20 % [6]. The symptoms associated
with IPF include breathlessness, cough, fatigue, anxiety,
and depression [3, 4]. Patients also report concerns about
loss of fitness, loss of weight, and the impact of both the
condition and interventions on their nutritional state [7].
Therefore, involving patients in the decision-making
process on all aspects of care management and participa-
tion in research requires some expediency.
Recent priorities in IPF have focussed on understanding
the natural history of the disease and the pathobiology.
Progress to date has enhanced this understanding [8] and
delivered two new effective pharmacological therapies that
appear to slow disease progression: pirfenidone (Esbriet:
InterMune®), approved for use in Europe (in 2011), the
UK (in 2013), and the US (in 2014) and nintedanib (OFEV:
Boerhinger®), awaiting final approvals in the UK and ap-
proved by the US Federal Drug Administration (FDA) in
2014. Nevertheless, there is still a need to characterise the
impacts of these therapies on patients’ perceived health
status and overall quality of life. The next generation of
IPF clinical trials will require design modifications to ac-
count for the availability of existing therapies [9]. Collard
et al. [9] propose a coalition of stakeholders including pa-
tients and advocacy groups to contribute to trial design
bringing creativity and flexibility. As a rare disease, IPF re-
search will require global collaboration to combine efforts,
standardise approaches, and share expertise. Patient
organisations are particularly important, offering add-
itional incentives.
IPF researchers have experienced challenges due to the
lack of consensus in optimal outcome measures in IPF
trials [10–14]. Although some experts believe that it is
not a surrogate for mortality [15], forced vital capacity
(FVC) has become the favoured primary endpoint amongst
trial designers. This is due, in part, to its reliability and re-
producibility across pulmonary function testing laboratories
and equipment and its ability to predict mortality in several
observational studies.
Meanwhile, patient-centred outcomes, such as self-report
measures to assess how patients feel and function in their
daily lives, have been, at best, included as lower-tier
endpoints. Relegation of patient-centred outcomes likely
stems from an absence of IPF-specific measures, a lack of
longitudinal data to support validity, and uncertainty
regarding the significance of score values or minimal
important differences. This impacts the meaningfulness
of many data generated in IPF trials, shifting the focus
away from the patient experience.We support the view of Collard et al. [9] calling for a
shift in emphasis in IPF clinical research and trial design.
We propose a strategy that places the patient at the heart
of research to enrich our understanding of what living
with IPF is like. Primarily, we advocate a pragmatic
approach in selecting methodologies best suited to the
research problem; mixed methods that employ both
quantitative and qualitative designs should be considered,
acknowledging the limitations and complementary nature
of both, followed by the involvement of patients in the re-
search process as active investigators, and finally, paying
closer attention to the choice of patient-centred outcomes
to ensure we are measuring what is important to patients.
The selection of patient-reported outcomes (PROs) based
on familiarity is no longer acceptable.
Discussion
Patient-centred research
The Patient-Centred Outcomes Research Institute (PCORI)
strives to generate reliable data that patients, caregivers,
and practitioners can use to make informed decisions and
to assess the value of healthcare options [16]. An evaluation
protocol is proposed by the Patient-Centred Outcomes Re-
search trust fund to determine how patient-centred re-
search impacts healthcare [17]. Studies funded by PCORI
will be evaluated according to three components: financial
accountability, level of adherence to the principles of
patient-centredness (defined as relevant, pragmatic, feasible,
and participatory), and whether they make a difference to
healthcare quality outcomes.
In the UK, the National Institute for Health Research
has funded, for two decades, a national advisory group,
INVOLVE©, to promote and monitor active public in-
volvement in National Health Service (NHS) public health
and social care research. Many research funding streams
in the US, Netherlands, and the UK (including National
Institute for Health Research funded studies) require well-
documented evidence of patient/public involvement from
protocol development through to dissemination and im-
plementation of results. Ethical review boards also ensure
patient’s interests are represented at the outset.
Recently formed working groups with a remit to deter-
mine future directions in IPF research [18] or to identify
core sets of domains and instruments for use in clinical
trials [19] have included patient representatives; unfortu-
nately, there is no mention of any patient input to a recent
UK round table discussion on improving care for IPF pa-
tients [20]. The British Lung Foundation has identified IPF
as a research priority and includes patient representatives
on its IPF research advisory board. International IPF-
specific charities and advocacy groups have developed a
strong patient voice discussing and disseminating research
information. The International Society for Quality of Life
(ISOQOL) hosts a Special Interest Group for patient and
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The American Thoracic Society/European Respiratory
Society/Japanese Respiratory Society/Latin American
Thoracic Association Clinical Practice Guideline [21]
development group included a patient representative and
his positive contribution was extensively acknowledged.
Sadly, he passed away before the guideline was published,
highlighting the dilemma faced by IPF researchers/clini-
cians. IPF is associated with an unpredictable trajectory
and high mortality. Research processes from conception,
through design, ethical approvals, study conduct, and dis-
semination are lengthy. Realistic planning and sensitive
thought needs to be given as to how to engage with pa-
tients in the most meaningful way. It may be expedient to
collaborate with larger patient/carer groups, under agreed
terms of reference with clearly defined roles.
Essential components of patient-centred approaches
include understanding what is important to patients,
respecting each individual’s health beliefs, values, and
judgments [22]. Measuring levels of patient satisfaction
correlates with participation in research [16], although it is
likely that satisfaction is a more sensitive marker of the
patient-professional relationship than the outcome per se.
Nonetheless, ‘satisfaction’ should be considered as an out-
come measure in the research encounter.Drivers for PROs
In the UK, there has been a recurring call for patient in-
volvement in health service development and delivery
(progressively including research) since 2002 [23–26].
However, the UK is divided. England places greater em-
phasis than its devolved nations on patient choice and
transparency in the NHS and, in what is perceived as a
landmark development, introduced a PROs programme
to measure patients’ self-reported health status in 2009.
Initially, four surgical procedures (inguinal hernia repair,
hip and knee replacements, and varicose vein surgery)
were included. The NHS Executive has subsequently ex-
tended the PRO programme to cancer, mental ill-health,
and six chronic conditions, including asthma and chronic
obstructive pulmonary disease [27].
The National Institute for Health and Care Excellence
(NICE) Quality Standards have a wider scope to drive the
use of PROs, generating patient-derived outcome data and
measuring change in HRQoL of both patients and carers
as benchmarks that commissioners and providers use as
performance indicators for NHS care. The 24 designated
specialist centres for Interstitial Lung Diseases (and IPF in
particular) in the UK must adhere to NICE Quality Stan-
dards [28]. This core minimum standard is enhanced by
the NICE Clinical guideline [29] that advocates patient-
centred care in the diagnosis and management of IPF.PCORI, in the US, advocates the use of PROs with equal
enthusiasm [30].
Patient-centred outcomes
The most well-known patient-centred outcomes are PRO
measures that capture what is meaningful and valuable to
the individual patient [31]. Confirming what is meaningful
is accomplished through open dialogue with patients and
must be initiated at the beginning of the process. In fact,
the entire process of endpoint development and selection
must be built around – and ideally in part, by – the
patient, rather than the clinician-investigator. A PRO
is defined as:
“Any report coming directly from the patient without
interpretation by a third party about how they feel or
function in relation to a health condition and a given
intervention” [32].
Collection of PRO data enables clinicians to access in-
formation on outcome variations, to advance person-
centredness, and to capture the physical, emotional, and
social domains of health that will be important for
healthcare provision. This has been shown to impact
clinician-patient communication [33–35], assist with
shared decision-making [36], and contribute to the suc-
cess of the encounter [37].
A PRO must also meet psychometric criteria that any
other useful clinical endpoint is required to meet. It
should be reliable (scores remain unchanged if there is
no change in the construct it measures), valid (measure
what it purports to measure), and responsive to changes
in the construct it measures (regardless of the aetiology
of those changes) [38]. It is helpful if scores are predict-
ive of clinical outcome and a threshold for minimal im-
portant differences is known [39].
The frequency with which PRO data are collected is
variable. ISOQOL recommend that condition-specific PRO
data be collected at least every 6 months; for patients
requiring regular treatment, such as chemotherapy, weekly
data collection is recommended [40]. In clinical research,
a PRO can facilitate discussion, promote self-efficacy,
improve outcomes, increase satisfaction, and improve
adherence to and measurement of the impact of the
intervention. Given the uncertain trajectory of IPF, we
advocate PROs are administered at all points of significant
transition – for example, at exacerbation or at dose titra-
tion of therapies such as pirfenidone and nintedanib. The
IPF integrated care pathway (a tool that formalises the
care processes) must be able to accommodate this.
Selecting a PRO for IPF
The main endpoints used in IPF research have typically
included time to disease progression, transplant, or death;
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capacity of the lung for carbon monoxide, or distance
walked in 6-minute walk test); or the occurrence of
complications (respiratory failure, hospitalization, or acute
exacerbations). Whilst these clinical endpoints offer
objective measures of decline, they fail to directly capture
aspects most meaningful to patients, such as symptom
frequency/severity, physical functional status, level of
independence, social functioning, and psychological state.
NICE recommends that interventional studies of patients
with IPF should include, as endpoints, a breathlessness
score and a measure of HRQoL that have been validated in
an IPF cohort [29]. The European Lung Foundation
emphasizes the importance of enabling patients with
IPF to be able to report on their quality of life, in par-
ticular to facilitate discussion on the IPF-imposed need
to adjust life goals [7].
Symptoms measures, health status, and quality of life
questionnaires are being integrated into IPF research, but
there is a limited number of candidate PROs validated for
use in IPF cohorts. Given the new era of clinical trials, we
need to be able to select from a range of complementary
patient-centred PROs that conform to FDA criteria, have
robust psychometric properties, and are available in
multiple languages to enable global collaboration. IPF
Registries may offer the opportunity to create larger data
sets to enable longitudinal evaluation of IPF PROs.
Currently, there is only one IPF-specific PRO: A Tool to
Assess Quality of Life in IPF (ATAQ-I) [41]. It was created
using methodology concordant with FDA recommenda-
tions (i.e. originating through open-floor, patient-led discus-
sion) [31]. The original version with 89 items is associated
with a moderate burden to complete. The ATAQ-I has
been modified [42] and a subsequent modified version has
been submitted for FDA approval. Prospective studies
are still needed to establish the ATAQ-I specificity in
IPF populations.
The St George’s Respiratory Questionnaire (SGRQ)
[43] has been used in IPF studies and its psychometric
properties reviewed in 30 studies to date [44]. The impact
and activity domains and the total score were found to
have greater reliability to detect change in health status
compared with the symptom domain in IPF populations.
This was most evident in the INPULSIS I and INPULSIS
II phase 3 trials to investigate the impact of nintedanib
on IPF [45]. Whilst the SGRQ is not the optimal PRO
for HRQoL, it is considered acceptable for use in IPF
populations. An IPF-specific modified version has also
been developed: the SGRQ-I (SGRQ–IPF) [46].
Another HRQoL measure for patients diagnosed with
interstitial lung disease has also been developed in a
population with predominantly connective tissue inter-
stitial lung disease, the King’s Brief Interstitial Lung
Disease questionnaire [47]. Its utility in IPF is currentlybeen explored. We await reports from longitudinal studies
on its stability as well as that of the SGRQ-I and ATAQ-I
in IPF populations over time.
A body of literature exists to support the prognostic
value of the generic Medical Research Council (MRC)
dyspnoea scale as an outcome measure in IPF. Patient-
reported dyspnoea has been shown to be the single stron-
gest predictor of mortality in patients with IPF [48] and
correlates strongly with quality of life [49]. The modified
MRC score has been shown to have prognostic value in
predicting survival [50] and in detecting disease progres-
sion [51] in IPF. Holland et al. [52] reported that the MRC
score is also an independent predictor of anxiety and
depression in a mixed interstitial lung disease cohort.
As a five-item questionnaire, the burden is light and the
MRC is suitable for both clinical and research contexts.
The University of California San Diego Shortness of
Breath Questionnaire [53], frequently cited in the IPF
literature, was used as a secondary outcome measure in
the Capacity (phase II and III) [54–56] and Ascend
(phase III) trials [57]. Whilst the rate of decline of FVC
in the treatment group was significantly reduced (P <0.001)
and evident by week 13, the impact of pirfenidone on
the experience of breathlessness did not achieve statistical
significance with the questionnaire in this study.
The PROs used to date in IPF research fail to address
certain aspects deemed important by patients. For ex-
ample, fatigue is a greater concern than breathlessness
for many patients with IPF [58]. Further, whilst textbooks
describe dry cough in patients with IPF, patients often
report being troubled by productive cough and describe
exhausting regimens of phlegm clearance. Without en-
gaging with patients such important aspects are missed.
Patients as co-investigators
We believe that conducting qualitative research (i.e. in-
depth patient interviews and/or focus groups) prior to
designing a study is paramount to patient-centred re-
search, including patients as members of the research
team and using their expertise – they are, after all, the
true experts on living with their disease – to define and
refine interventions, select outcome measures, and dis-
seminate results [59–62]. We increasingly hear the patient
voice at international respiratory conferences, where a
unique perspective is offered complementing that of the
clinician-researcher.
Contributing to basic science and pre-clinical re-
search may be more challenging and requires a greater
level of technical knowledge and specific training for
the research team. However, it is proposed that patient
involvement in non-clinical research gives rise to experi-
ential knowledge that adds validity to the process. The
challenge lies in translating and applying this knowledge
appropriately [63].
Russell et al. BMC Medicine  (2015) 13:240 Page 5 of 7Patients’ expertise lies in conveying what it means to
live with IPF and how living with IPF impacts life in all
its domains. Given the inherent morbidity and mortality
associated with IPF, a flexible approach is needed as to
how to operationalise the inclusion of patients on the
team. Patients are not always able to travel. Telephone
conference facilities should be available, supplemental
oxygen provided to patients who need it during meetings,
meetings should be relatively short and planned well in
advance, and training germane to the research must
be identified and offered. Thought needs to be given
to appropriate remuneration if patients are to be truly
perceived as partners/co-investigators.
Patient-centredness may also include the involvement
of care-givers as co-investigators. Caregivers are invalu-
able enablers in the research process offering further
insight into the perspective of the one they care for.
Summary
A more patient-centred approach in this new era of IPF
research is an urgent priority. Expanding patient consult-
ation in research design processes, to ensure that research
questions address what is important to patient populations,
and subsequently actively involving patients in the conduct
of studies, the dissemination process, and ongoing collabor-
ation is achievable. Patients or their designated carer must
also receive feedback regarding the results of the research
in which they have participated. This is likely to assist with
retention and future recruitment. It is essential that we
capture patients’ level of satisfaction with all aspects of
the research process.
As new therapies for IPF emerge, individualised ap-
proaches may result in new regimens of combination
therapies. Collecting PROs has never been more import-
ant to enable us to determine what is acceptable and toler-
able for an individual over time. In addition, these data
collectively determine the impact of ‘supportive care only’
and ‘single’ or ‘combined therapies’ on health status in IPF
populations. We must critically appraise our choice of
PRO and the time points at which it is administered.
Patient centred research is a dynamic process achieved
by involving and working with patients at all levels from
pre-clinical research and clinical trials through to post-
marketing surveillance. Contemporary patient-centred
PROs are not without limitation but they do add value
and remind and enable us to regard the patient before
the condition.
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